Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas

Small cell prostate carcinoma ( SCPC) morphology is rare at initial diagnosis but often emerges during prostate cancer progression and portends a dismal prognosis. It does not express androgen receptor ( AR) or respond to hormonal therapies. Clinically applicable markers for its early detection and treatment with effective chemotherapy are needed. Our studies in patient tumor- derived xenografts ( PDX) revealed that AR- negative SCPC ( AR- SCPC) expresses neural development genes instead of the prostate luminal epithelial genes characteristic of AR- positive castration- resistant adenocarcinomas ( AR+ADENO). We hypothesized that the differences in cellular lineage programs are reflected in distinct epigenetic profiles. To address this hypothesis, we compared the DNA methylation profiles of AR- and ARC PDX using methylated CpG island amplification and microarray ( MCAM) analysis and identified a set of differentially methylated promoters, validated in PDX and corresponding donor patient samples. We used the Illumina 450K platform to examine additional regions of the genome and the correlation between the DNA methylation profiles of the PDX and their corresponding patient tumors. Struck by the low frequency of AR promoter methylation in the AR- SCPC, we investigated this region's specific histone modification patterns by chromatin immunoprecipitation. We found that the AR promoter was enriched in silencing histone modifications ( H3K27me3 and H3K9me2) and that EZH2 inhibition with 3- deazaneplanocin A ( DZNep) resulted in AR expression and growth inhibition in AR SCPC cell lines. We conclude that the epigenome of AR- is distinct from that of AR+ castration- resistant prostate carcinomas, and that the AR-phenotype can be reversed with epigenetic drugs.